The pan-PPAR agonist bezafibrate alone has no significant effect on the proliferation and apoptosis of PC, but its combined use with GSK126 could further enhance the anti-PC cancer effect, suggesting that GSK126 and bezafibrate have synergistic effects at certain concentrations. Here, PPARA is linked to pachyonychia congenita.